drugset / Trial / NCT07615101
Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
NaSingle-groupOpen-labelDiagnostic
Summary
The investigators are imaging patients with newly diagnosed prostate cancer using a new Positron Emission Tomography (PET) imaging agent (68Ga-NYM032) in order to evaluate the safety and diagnostic performance.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2027-06-30
- Completion
- 2027-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-NYM032 | Small molecule | — | Intravenous |
Indications
No indication recorded.